Discover Advancements in the Treatment of Myelosuppression

Lung cancer is the leading cause of cancer-related death in the United States.¹ About 13% of all lung cancer cases in the United States are small cell lung cancer (SCLC), and most patients are diagnosed with extensive-stage (ES)-SCLC.^2,3 The prognosis for patients with SCLC is poor, with an overall 5-year survival rate of 6% and just 3% among those with distant metastasis.²

Systemic chemotherapy in combination with immune checkpoint inhibitors is the standard of care for patients with ES-SCLC.⁴ However, these regimens present a treatment challenge due to multilineage myelosuppression. Myelosuppression increases a patient’s risk for bleeding complications, infections, and secondary malignancies,⁵ and is the most common reason for dose reductions, delays, and discontinuation of chemotherapy.

Join Dr. Kim, Dr. Mohamed, and Dana Herndon, RN, in a live broadcast to learn more about the current treatment landscape of chemotherapy-induced myelosuppression in patients with ES-SCLC. These leading experts will discuss the clinical data, safety, and considerations of a therapeutic option for chemotherapy-induced myelosuppression.

Program Objectives

• Review the burden and current treatment landscape of chemotherapy-induced myelosuppression
• Introduce the mechanism of action and safety and efficacy data
• Explore adverse reactions, dosing and administration, and the patient support program

References:

1. American Cancer Society. Key statistics for lung cancer. Accessed January 11, 2021. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
2. American Society of Clinical Oncology. Lung cancer - small cell: statistics. Accessed January 11, 2021. https://www.cancer.net/cancer-types/lung-cancer-small-cell/statistics
3. American Society of Clinical Oncology. Lung cancer - small cell: stages. Accessed January 11, 2021. https://www.cancer.net/cancer-types/lung-cancer-small-cell/stages
4. National Comprehensive Cancer Network. Small Cell Lung Cancer (Version 1.2021). Accessed August 11, 2020. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.
5. Kurtin S. Myeloid toxicity of cancer treatment. J Adv Pract Oncol. 2012;3(4):209-224.